Clinical Trials Insight: 700028315
Phase of Trial: Phase I
Latest Information Update: 19 Nov 2009
At a glance
- Drugs THR 317 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors BioInvent International; ThromboGenics
- 19 Nov 2009 Results were presented at 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009).
- 03 Jun 2008 Status changed to completed, reported in a ThromboGenics media release.
- 03 Jun 2008 Positive tolerability results announced in a Thrombogenics media release. Primary endpoints met.